NFKB1 and acute lymphoblastic leukemia: The credentials of cAMP as an antiapoptotic factor in BCP-ALL cells [19] and its ability to hyperactivate NF-κB lend further support to our notion that inhibitors of cAMP signaling pathway might prove beneficial in treatment of BCP-ALL tumors.